Nutraceuticals in cardiovascular prevention: Lessons from studies on endothelial function

Cardiovascular Therapeutics

Volumn 28, Issue 4, 2010, Pages 187-201

  Zuchi, Cinzia ^a,b,c   Ambrosio, Giuseppe ^c   Lüscher, Thomas F ^a,b   Landmesser, Ulf ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Antioxidant vitamins; Cardiovascular prevention; Endothelial function, Nutraceuticals

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; COLECALCIFEROL; CYANOCOBALAMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ERGOCALCIFEROL; FISH OIL; FLAVANOL DERIVATIVE; FOLIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; NICOTINIC ACID; NITRIC OXIDE; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PYRIDOXINE; RESVERATROL; CARDIOVASCULAR AGENT;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; ENDOTHELIAL DYSFUNCTION; GRAPE JUICE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; MULTICENTER STUDY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING; TEA; WALNUT; ANIMAL; CARDIOVASCULAR DISEASES; DIET; DRUG EFFECTS; EVIDENCE BASED MEDICINE; FUNCTIONAL FOOD; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIET; DIETARY SUPPLEMENTS; ENDOTHELIUM, VASCULAR; EVIDENCE-BASED MEDICINE; FUNCTIONAL FOOD; HUMANS; TREATMENT OUTCOME;

EID: 77954368732     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2010.00165.x     Document Type: Review

References (133)

1. Bjelakovic G, Gluud C. Surviving antioxidant supplements. J Natl Cancer Inst 2007 99 : 742 743.
2. Brower V. Nutraceuticals: Poised for a healthy slice of the healthcare market? Nat Biotechnol 1998 16 : 728 731.
3. Zeisel SH. Regulation of "nutraceuticals". Science 1999 285 : 1853 1855.
4. Mehta J. Intake of antioxidants among American cardiologists. Am J Cardiol 1997 79 : 1558 1560.
5. Rimm EB, Stampfer MJ, Ascherio A, et al. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993 328 : 1450 1456.
6. Stampfer MJ, Hennekens CH, Manson JE, et al. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993 328 : 1444 1449.
7. Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation 2004 109 (21 Suppl 1 II27 II33.
8. Lerman A, Zeiher AM. Endothelial function: Cardiac events. Circulation 2005 111 : 363 368.
9. Modena MG, Bonetti L, Coppi F, et al. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol 2002 40 : 505 510.
10. Sorrentino SA, Bahlmann FH, Besler C, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: Restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2007 116 : 163 173.
11. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010 121 : 110 122.
12. Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001 89 : E1 E7.
13. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005 353 : 999 1007. (Pubitemid 41262334)
14. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003 348 : 593 600.
15. Landmesser U, Harrison DG. Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation 2001 104 : 2638 2640.
16. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ Res 2000 87 : 840 844.
17. Khaw KT, Bingham S, Welch A, et al. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: A prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 2001 357 : 657 663.
18. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002 360 : 23 33.
19. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: Systematic review and meta-analysis. JAMA 2007 297 : 842 857.
20. Miller ER, 3rd., Pastor-Barriuso R, Dalal D, et al. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005 142 : 37 46.
21. Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: Meta-analysis of randomised trials. Lancet 2003 361 : 2017 2023.
22. Sesso HD, Buring JE, Christen WG, et al. Vitamins E and C in the prevention of cardiovascular disease in men: The Physicians' Health Study II randomized controlled trial. JAMA 2008 300 : 2123 2133.
23. Keaney JF, Jr., Gaziano JM, Xu A, et al. Low-dose alpha-tocopherol improves and high-dose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest 1994 93 : 844 851.
24. Raitakari OT, Adams MR, McCredie RJ, et al. Oral vitamin C and endothelial function in smokers: Short-term improvement, but no sustained beneficial effect. J Am Coll Cardiol 2000 35 : 1616 1621.
25. Kinlay S, Behrendt D, Fang JC, et al. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function. J Am Coll Cardiol 2004 43 : 629 634.
26. Meilhac O, Ramachandran S, Chiang K, et al. Role of arterial wall antioxidant defense in beneficial effects of exercise on atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2001 21 : 1681 1688.
27. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001 345 : 1583 1592.
28. Meagher EA, Barry OP, Lawson JA, et al. Effects of vitamin E on lipid peroxidation in healthy persons. JAMA 2001 285 : 1178 1182.
29. Brigelius-Flohe R, Davies KJ. Is vitamin E an antioxidant, a regulator of signal transduction and gene expression, or a 'junk' food? Comments on the two accompanying papers: "Molecular mechanism of alpha-tocopherol action" by A. Azzi and "Vitamin E, antioxidant and nothing more" by M. Traber and J. Atkinson. Free Radic Biol Med 2007 43 : 2 3.
30. Blumberg JB, Frei B. Why clinical trials of vitamin E and cardiovascular diseases may be fatally flawed. Commentary on "The relationship between dose of vitamin E and suppression of oxidative stress in humans Free Radic Biol Med 2007 43 : 1374 1376.
31. Roberts LJ, 2nd., Oates JA, Linton MF, et al. The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med 2007 43 : 1388 1393.
32. Bowry VW, Ingold KU, Stocker R. Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant. Biochem J 1992 288 (Pt 2 341 344.
33. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002 82 : 47 95.
34. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986 74 : 1124 1136.
35. Yellon DM, Downey JM. Preconditioning the myocardium: From cellular physiology to clinical cardiology. Physiol Rev 2003 83 : 1113 1151.
36. Napoli C, Liguori A, Chiariello M, et al. New-onset angina preceding acute myocardial infarction is associated with improved contractile recovery after thrombolysis. Eur Heart J 1998 19 : 411 419. (Pubitemid 28120721)
37. Kloner RA, Shook T, Przyklenk K, et al. Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning? Circulation 1995 91 : 37 45.
38. Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size. A role for ischemic preconditioning. Circulation 1995 91 : 291 297.
39. Hirai T, Fujita M, Yamanishi K, et al. Significance of preinfarction angina for preservation of left ventricular function in acute myocardial infarction. Am Heart J 1992 124 : 19 24.
40. Matsuda Y, Ogawa H, Moritani K, et al. Effects of the presence or absence of preceding angina pectoris on left ventricular function after acute myocardial infarction. Am Heart J 1984 108 (4 Pt 1 955 958.
41. Kloner RA, Shook T, Antman EM, et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: An ancillary study in TIMI-9B. Circulation 1998 97 : 1042 1045.
42. Solomon SD, Anavekar NS, Greaves S, et al. Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling. J Am Coll Cardiol 2004 43 : 1511 1514.
43. Tritto I, D'Andrea D, Eramo N, et al. Oxygen radicals can induce preconditioning in rabbit hearts. Circ Res 1997 80 : 743 748.
44. Baines CP, Goto M, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 1997 29 : 207 216.
45. Tritto I, Ambrosio G. Role of oxidants in the signaling pathway of preconditioning. Antioxid Redox Signal 2001 3 : 3 10.
46. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996 347 : 781 786.
47. Rapola JM, Virtamo J, Ripatti S, et al. Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet 1997 349 : 1715 1720.
48. Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996 93 : 1107 1113.
49. Heitzer T, Just H, Munzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 1996 94 : 6 9.
50. Heitzer T, Yla Herttuala S, Wild E, et al. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol 1999 33 : 499 505.
51. Plantinga Y, Ghiadoni L, Magagna A, et al. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 2007 20 : 392 397.
52. Sugden JA, Davies JI, Witham MD, et al. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008 25 : 320 325.
53. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab 2009 94 : 4023 4030.
54. Shirodaria C, Antoniades C, Lee J, et al. Global improvement of vascular function and redox state with low-dose folic acid: Implications for folate therapy in patients with coronary artery disease. Circulation 2007 115 : 2262 2270.
55. Potter K, Hankey GJ, Green DJ, et al. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: A randomized controlled trial and meta-analysis. BMC Cardiovasc Disord 2008 8 : 24.
56. Kuvin JT, Ramet ME, Patel AR, et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: Enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002 144 : 165 172.
57. Benjo AM, Maranhao RC, Coimbra SR, et al. Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: Effects of niacin treatment. Atherosclerosis 2006 187 : 116 122.
58. Warnholtz A, Wild P, Ostad MA, et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis 2009 204 : 216 221.
59. Westphal S, Borucki K, Taneva E, et al. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007 193 : 361 365.
60. Lee JM, Robson MD, Yu LM, et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: A randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009 54 : 1787 1794.
61. Holick MF. Vitamin D deficiency. N Engl J Med 2007 357 : 266 281.
62. Merke J, Milde P, Lewicka S, et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 1989 83 : 1903 1915.
63. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002 110 : 229 238.
64. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008 117 : 503 511.
65. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: A systematic review and meta-analysis. J Hypertens 2009 27 : 1948 1954.
66. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007 115 : 846 854.
67. He K, Song Y, Daviglus ML, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: A meta-analysis of cohort studies. Circulation 2004 109 : 2705 2711.
68. Bjerregaard LJ, Joensen AM, Dethlefsen C, et al. Fish intake and acute coronary syndrome. Eur Heart J 2010 31 : 29 34.
69. Oomen CM, Feskens EJ, Rasanen L, et al. Fish consumption and coronary heart disease mortality in Finland, Italy, and The Netherlands. Am J Epidemiol 2000 151 : 999 1006.
70. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 2006 296 : 1885 1899.
71. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002 106 : 2747 2757.
72. De Caterina R, Zampolli A. Omega-3 fatty acids, atherogenesis, and endothelial activation. J Cardiovasc Med (Hagerstown) 2007 8 (Suppl 1 S11 S14.
73. Shah AP, Ichiuji AM, Han JK, et al. Cardiovascular and endothelial effects of fish oil supplementation in healthy volunteers. J Cardiovasc Pharmacol Ther. 2007 12 : 213 219.
74. Goodfellow J, Bellamy MF, Ramsey MW, et al. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. J Am Coll Cardiol 2000 35 : 265 270.
75. Tagawa T, Hirooka Y, Shimokawa H, et al. Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertens Res 2002 25 : 823 829. (Pubitemid 36024636)
76. Tagawa H, Shimokawa H, Tagawa T, et al. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol 1999 33 : 633 640.
77. Morgan DR, Dixon LJ, Hanratty CG, et al. Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure. Am J Cardiol 2006 97 : 547 551.
78. Schiano V, Laurenzano E, Brevetti G, et al. Omega-3 polyunsaturated fatty acid in peripheral arterial disease: Effect on lipid pattern, disease severity, inflammation profile, and endothelial function. Clin Nutr 2008 27 : 241 247.
79. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003 166 : 85 93. (Pubitemid 35449604)
80. Angerer P, Kothny W, Stork S, et al. Effect of dietary supplementation with omega-3 fatty acids on progression of atherosclerosis in carotid arteries. Cardiovasc Res 2002 54 : 183 190.
81. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999 130 : 554 562.
82. Sacks FM, Stone PH, Gibson CM, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995 25 : 1492 1498.
83. Baldassarre D, Amato M, Eligini S, et al. Effect of n-3 fatty acids on carotid atherosclerosis and haemostasis in patients with combined hyperlipoproteinemia: A double-blind pilot study in primary prevention. Ann Med. 2006 38 : 367 375.
84. Ros E, Nunez I, Perez-Heras A, et al. A walnut diet improves endothelial function in hypercholesterolemic subjects: A randomized crossover trial. Circulation 2004 109 : 1609 1614.
85. Duffy SJ, Keaney JF, Jr., Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001 104 : 151 156. (Pubitemid 32655830)
86. Fisher ND, Hughes M, Gerhard-Herman M, et al. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 2003 21 : 2281 2286.
87. Nagaya N, Yamamoto H, Uematsu M, et al. Green tea reverses endothelial dysfunction in healthy smokers. Heart 2004 90 : 1485 1486.
88. Heiss C, Kleinbongard P, Dejam A, et al. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol 2005 46 : 1276 1283.
89. Flammer AJ, Hermann F, Sudano I, et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007 116 : 2376 2382.
90. Balzer J, Rassaf T, Heiss C, et al. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. J Am Coll Cardiol 2008 51 : 2141 2149.
91. Stein JH, Keevil JG, Wiebe DA, et al. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 1999 100 : 1050 1055.
92. Agewall S, Wright S, Doughty RN, et al. Does a glass of red wine improve endothelial function? Eur Heart J 2000 21 : 74 78.
93. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999 354 : 447 455.
94. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients: A randomised open-label, blinded endpoint analysis. Lancet 2007 369 : 1090 1098.
95. Hu FB, Stampfer MJ, Manson JE, et al. Dietary intake of alpha-linolenic acid and risk of fatal ischemic heart disease among women. Am J Clin Nutr 1999 69 : 890 897.
96. Ascherio A, Rimm EB, Giovannucci EL, et al. Dietary fat and risk of coronary heart disease in men: Cohort follow up study in the United States. BMJ 1996 313 : 84 90.
97. Djousse L, Pankow JS, Eckfeldt JH, et al. Relation between dietary linolenic acid and coronary artery disease in the National Heart, Lung, and Blood Institute Family Heart Study. Am J Clin Nutr 2001 74 : 612 619.
98. Campos H, Baylin A, Willett WC. Alpha-linolenic acid and risk of nonfatal acute myocardial infarction. Circulation 2008 118 : 339 345.
99. Singh RB, Niaz MA, Sharma JP, et al. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival-4. Cardiovasc Drugs Ther 1997 11 : 485 491.
100. Singh RB, Dubnov G, Niaz MA, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): A randomised single-blind trial. Lancet 2002 360 : 1455 1461.
101. Bemelmans WJ, Broer J, Feskens EJ, et al. Effect of an increased intake of alpha-linolenic acid and group nutritional education on cardiovascular risk factors: The Mediterranean Alpha-linolenic Enriched Groningen Dietary Intervention (MARGARIN) study. Am J Clin Nutr 2002 75 : 221 227.
102. McCully KS. Vascular pathology of homocysteinemia: Implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969 56 : 111 128.
103. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002 288 : 2015 2022.
104. Vanuzzo D, Pilotto L, Lombardi R, et al. Both vitamin B6 and total homocysteine plasma levels predict long-term atherothrombotic events in healthy subjects. Eur Heart J 2007 28 : 484 491.
105. de Bree A, van Mierlo LA, Draijer R. Folic acid improves vascular reactivity in humans: A meta-analysis of randomized controlled trials. Am J Clin Nutr 2007 86 : 610 617.
106. Bazzano LA, Reynolds K, Holder KN, et al. Effect of folic acid supplementation on risk of cardiovascular diseases: A meta-analysis of randomized controlled trials. JAMA 2006 296 : 2720 2726.
107. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008 299 : 2027 2036.
108. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 2007 298 : 1163 1170.
109. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA 2008 300 : 795 804.
110. Langman LJ, Ray JG, Evrovski J, et al. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: More evidence from a case-control study. Arch Intern Med 2000 160 : 961 964.
111. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med 1998 158 : 2101 2106.
112. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation. 1997 95 : 1777 1782.
113. Eichinger S, Stumpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998 80 : 566 569.
114. den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007 109 : 139 144.
115. Ray JG, Kearon C, Yi Q, et al. Homocysteine-lowering therapy and risk for venous thromboembolism: A randomized trial. Ann Intern Med 2007 146 : 761 767.
116. Kuhnau J. The flavonoids. A class of semi-essential food components: Their role in human nutrition. World Rev Nutr Diet 1976 24 : 117 191.
117. Hertog MG, Hollman PC, Katan MB, et al. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 1993 20 : 21 29.
118. Knekt P, Jarvinen R, Reunanen A, et al. Flavonoid intake and coronary mortality in Finland: A cohort study. BMJ 1996 312 : 478 481.
119. Peters U, Poole C, Arab L. Does tea affect cardiovascular disease? A meta-analysis. Am J Epidemiol 2001 154 : 495 503.
120. Hertog MG, Sweetnam PM, Fehily AM, et al. Antioxidant flavonols and ischemic heart disease in a Welsh population of men: The Caerphilly Study. Am J Clin Nutr 1997 65 : 1489 1494.
121. Mukamal KJ, Maclure M, Muller JE, et al. Tea consumption and mortality after acute myocardial infarction. Circulation 2002 105 : 2476 2481.
122. Heiss C, Schroeter H, Balzer J, et al. Endothelial function, nitric oxide, and cocoa flavanols. J Cardiovasc Pharmacol 2006 47 (Suppl 2 S128 S135 discussion S172-S126.
123. Di Castelnuovo A, Rotondo S, Iacoviello L, et al. Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 2002 105 : 2836 2844.
124. van Velden DP, Mansvelt EP, Fourie E, et al. The cardioprotective effect of wine on human blood chemistry. Ann N Y Acad Sci 2002 957 : 337 340.
125. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992 339 : 1523 1526.
126. Balestrieri ML, Fiorito C, Crimi E, et al. Effect of red wine antioxidants and minor polyphenolic constituents on endothelial progenitor cells after physical training in mice. Int J Cardiol 2008 126 : 295 297.
127. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955 54 : 558 559.
128. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008 101 : 20B 26B.
129. Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004 67 : 411 419.
130. Chapman MJ, Le Goff W, Guerin M, et al. Cholesteryl ester transfer protein: At the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 31 : 149 164.
131. Green PS, Vaisar T, Pennathur S, et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008 118 : 1259 1267.
132. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009 361 : 2113 2122.
133. Berge KG, Canner PL. Coronary drug project: Experience with niacin. Coronary Drug Project Research Group. Eur J Clin Pharmacol 1991 40 (Suppl 1 S49 S51.